Zhi Peng - Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Peking Univ

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 134 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Immune Checkpoint Inhibitors or Anti-Claudin 18.2 Antibodies? A Network Meta-Analysis for the Optimized First-Line Therapy of HER2-negative Gastric Cancer

Zhening Zhang,Tong Xie, Yingxuan Wang,Lin Shen,Xiaotian Zhang,Zhi Peng

Therapeutic Advances in Medical Oncology (2024)

引用0浏览0WOS引用

Abstract 6316: Exploring the Resistant Mechanism of CAR T Cell Therapy Targeting CLDN18.2 by Single-Cell Sequencing

Mingyang Ma,Changsong Qi,Chang Liu,Lei Jiang, Min Tao, Dan Liu,Panpan Zhang,Zhi Peng,Xiaotian Zhang,Jifang Gong,Yang Chen, Chunhong Zheng,Mi Deng,Lin Shen

Cancer Researchno. 6_Supplement (2024): 6316-6316

引用0浏览0引用

Claudin18.2-specific CAR T Cells in Gastrointestinal Cancers: Phase 1 Trial Interim Results

Changsong Qi,Jifang Gong,Jian Li, Dan Liu,Yanru Qin,Sai Ge,Miao Zhang,Zhi Peng,Jun Zhou,Yanshuo Cao,Xiaotian Zhang,Zhihao Lu,Ming Lu,Jiajia Yuan,Zhenghang Wang,Yakun Wang,Xiaohui Peng, Huiping Gao, Zhen Liu, Huamao Wang,Daijing Yuan, Jun Xiao, Hong Ma, Wei Wang, Zonghai Li,Lin Shen

NATURE MEDICINE（2024）

引用140浏览0WOSNATURE引用

140

Gut Microbial Metabolites in Cancer Therapy

Panwei Song,Zhi Peng,Xiaohuan Guo

Trends in Endocrinology & Metabolism (2024)

引用0浏览0引用

Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer (vol 16, 17588359241231253, 2024)

Zhening Zhang,Tong Xie, Yingxuan Wang,Lin Shen,Xiaotian Zhang,Zhi Peng

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2024)

引用0浏览0引用

Multi-omics of the Gut Microbial Ecosystem in Patients with Microsatellite-Instability-high Gastrointestinal Cancer Resistant to Immunotherapy

Siyuan Cheng,Zihan Han,Die Dai,Fang Li,Xiaotian Zhang,Ming Lu,Zhihao Lu,Xicheng Wang,Jun Zhou,Jian Li,Xiaohuan Guo,Panwei Song, Chuangzhao Qiu, Wei Shen,Qi Zhang,Ning Zhu,Xi Wang,Yan Tan,Yan Kou, Xiaochen Y. In,Lin Shen,Zhi Peng

CELL REPORTS MEDICINEno. 1 (2024)

引用0浏览0WOS引用

Microbiome and Cancer Immunotherapies

Haoyan Chen,Laurence Zitvogel,Zhi Peng,Xiaochen Yin,Florencia McAllister

Cell Reports Medicine（2024）

引用0浏览0WOS引用

Claudin18.2-targeted Chimeric Antigen Receptor T Cell-Therapy for Patients with Gastrointestinal Cancers: Final Results of CT041-CG4006 Phase 1 Trial

Changsong Qi,Chang Liu,Jifang Gong,Jian Li,Dan Liu,Xicheng Wang,Panpan Zhang,Yanru Qin,Miao Zhang,Zhi Peng,Jun Zhou,Xiaotian Zhang,Xiaohui Peng, Yumeng Wang,Zijing Zhang,Daijing Yuan,Zhen Liu,Raffaele Baffa,Zonghai Li,Lin Shen

Journal of Clinical Oncologyno. 16_suppl (2024): 2501-2501

引用0浏览0引用

Advances in MET Tyrosine Kinase Inhibitors in Gastric Cancer

Yifan Zhang,Lin Shen,Zhi Peng

Cancer Biology and Medicinepp.1-15, (2024)

引用0浏览0WOS引用

PTK7: an Underestimated Contributor to Human Cancer

Zhipeng Jin,Tianyu Guo, Xue Zhang,Xin Wang,Yefu Liu

Frontiers in oncology (2024): 1448695-1448695

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn